APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide CDMO Market Outlook and Growth Opportunities 2026

Report ID 174023610429 December 2025192 pages

Choose your research edition.

Industry ResearchPeptide CDMO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Peptide CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide CDMO Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide CDMO Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Peptide CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide CDMO market include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Peptide CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide CDMO market.

Peptide CDMO Segment by Company

Xinbang Pharma

ScinoPharm

SN Biopharm

Genscript

AmbioPharm

USV Peptides

Thermofischer

PolyPeptide

Piramal Pharma

JPT

CPC Scientific

CordenPharma

CBL

Bio Basic

Bachem

Peptide CDMO Segment by Type

APIs and Intermediates

FDF

Peptide CDMO Segment by Application

Commercial

Academic Research

Other

Peptide CDMO Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Peptide CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peptide CDMO key companies, revenue, market share, and recent developments.

3. To split the Peptide CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peptide CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide CDMO industry.

Chapter 3: Detailed analysis of Peptide CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peptide CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peptide CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide CDMO Industry Trends Table 2. Peptide CDMO Industry Drivers Table 3. Peptide CDMO Industry Opportunities and Challenges Table 4. Peptide CDMO Industry Restraints Table 5. Global Peptide CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide CDMO Revenue Share by Company (2021-2026) Table 7. Global Peptide CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peptide CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Peptide CDMO Company, Product Type & Application Table 10. Global Peptide CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peptide CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of APIs and Intermediates Table 15. Significant Companies of FDF Table 16. Global Peptide CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Peptide CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Peptide CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Peptide CDMO Sales Value Share by Type (2021-2026) Table 20. Global Peptide CDMO Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Commercial Table 22. Significant Companies of Academic Research Table 23. Significant Companies of Other Table 24. Global Peptide CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peptide CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Peptide CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Peptide CDMO Sales Value Share by Application (2021-2026) Table 28. Global Peptide CDMO Sales Value Share by Application (2027-2032) Table 29. Global Peptide CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Peptide CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Peptide CDMO Sales Value Share by Region (2021-2026) Table 32. Global Peptide CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Peptide CDMO Sales Value Share by Region (2027-2032) Table 34. Global Peptide CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Peptide CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Peptide CDMO Sales Value Market Share by Country (2021-2026) Table 37. Global Peptide CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Peptide CDMO Sales Value Market Share by Country (2027-2032) Table 39. Xinbang Pharma Company Information Table 40. Xinbang Pharma Business Overview Table 41. Xinbang Pharma Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Xinbang Pharma Peptide CDMO Product Portfolio Table 43. Xinbang Pharma Recent Development Table 44. ScinoPharm Company Information Table 45. ScinoPharm Business Overview Table 46. ScinoPharm Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. ScinoPharm Peptide CDMO Product Portfolio Table 48. ScinoPharm Recent Development Table 49. SN Biopharm Company Information Table 50. SN Biopharm Business Overview Table 51. SN Biopharm Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. SN Biopharm Peptide CDMO Product Portfolio Table 53. SN Biopharm Recent Development Table 54. Genscript Company Information Table 55. Genscript Business Overview Table 56. Genscript Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Genscript Peptide CDMO Product Portfolio Table 58. Genscript Recent Development Table 59. AmbioPharm Company Information Table 60. AmbioPharm Business Overview Table 61. AmbioPharm Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. AmbioPharm Peptide CDMO Product Portfolio Table 63. AmbioPharm Recent Development Table 64. USV Peptides Company Information Table 65. USV Peptides Business Overview Table 66. USV Peptides Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. USV Peptides Peptide CDMO Product Portfolio Table 68. USV Peptides Recent Development Table 69. Thermofischer Company Information Table 70. Thermofischer Business Overview Table 71. Thermofischer Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Thermofischer Peptide CDMO Product Portfolio Table 73. Thermofischer Recent Development Table 74. PolyPeptide Company Information Table 75. PolyPeptide Business Overview Table 76. PolyPeptide Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. PolyPeptide Peptide CDMO Product Portfolio Table 78. PolyPeptide Recent Development Table 79. Piramal Pharma Company Information Table 80. Piramal Pharma Business Overview Table 81. Piramal Pharma Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Piramal Pharma Peptide CDMO Product Portfolio Table 83. Piramal Pharma Recent Development Table 84. JPT Company Information Table 85. JPT Business Overview Table 86. JPT Peptide CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. JPT Peptide CDMO Product Portfolio Table 88. JPT Recent Development Table 89. CPC Scientific Company Information Table 90. CPC Scientific Business Overview Table 91. CPC Scientific Peptide CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. CPC Scientific Peptide CDMO Product Portfolio Table 93. CPC Scientific Recent Development Table 94. CordenPharma Company Information Table 95. CordenPharma Business Overview Table 96. CordenPharma Peptide CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. CordenPharma Peptide CDMO Product Portfolio Table 98. CordenPharma Recent Development Table 99. CBL Company Information Table 100. CBL Business Overview Table 101. CBL Peptide CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. CBL Peptide CDMO Product Portfolio Table 103. CBL Recent Development Table 104. Bio Basic Company Information Table 105. Bio Basic Business Overview Table 106. Bio Basic Peptide CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bio Basic Peptide CDMO Product Portfolio Table 108. Bio Basic Recent Development Table 109. Bachem Company Information Table 110. Bachem Business Overview Table 111. Bachem Peptide CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Bachem Peptide CDMO Product Portfolio Table 113. Bachem Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Peptide CDMO Product Image Figure 2. Global Peptide CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. APIs and Intermediates Image Figure 8. FDF Image Figure 9. Global Peptide CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Peptide CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Peptide CDMO Sales Value Share by Type (2021-2032) Figure 12. Commercial Image Figure 13. Academic Research Image Figure 14. Other Image Figure 15. Global Peptide CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Peptide CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Peptide CDMO Sales Value Share by Application (2021-2032) Figure 18. Global Peptide CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Peptide CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Peptide CDMO Sales Value (2021-2032) & (US$ Million) Figure 21. North America Peptide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Peptide CDMO Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Peptide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Peptide CDMO Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Peptide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Peptide CDMO Sales Value (2021-2032) & (US$ Million) Figure 27. South America Peptide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Peptide CDMO Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Peptide CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Peptide CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Peptide CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Peptide CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • APIs and Intermediates
  • FDF
Applications
  • Commercial
  • Academic Research
  • Other
Companies covered
  • Xinbang Pharma
  • ScinoPharm
  • SN Biopharm
  • Genscript
  • AmbioPharm
  • USV Peptides
  • Thermofischer
  • PolyPeptide
  • Piramal Pharma
  • JPT
  • CPC Scientific
  • CordenPharma
  • CBL
  • Bio Basic
  • Bachem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peptide CDMO Market Dynamics
  1. 2.1 Peptide CDMO Industry Trends
  2. 2.2 Peptide CDMO Industry Drivers
  3. 2.3 Peptide CDMO Industry Opportunities and Challenges
  4. 2.4 Peptide CDMO Industry Restraints
3 Peptide CDMO Market by Company
  1. 3.1 Global Peptide CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Peptide CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Peptide CDMO Company Ranking (2024-2026)
  4. 3.4 Global Peptide CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Peptide CDMO Company Product Type and Application
  6. 3.6 Global Peptide CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peptide CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peptide CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peptide CDMO Market by Type
  1. 4.1 Peptide CDMO Type Introduction
  2. 4.1.1 APIs and Intermediates
  3. 4.1.2 FDF
  4. 4.2 Global Peptide CDMO Sales Value by Type
  5. 4.2.1 Global Peptide CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide CDMO Sales Value by Type (2021-2032)
  7. 4.2.3 Global Peptide CDMO Sales Value Share by Type (2021-2032)
5 Peptide CDMO Market by Application
  1. 5.1 Peptide CDMO Application Introduction
  2. 5.1.1 Commercial
  3. 5.1.2 Academic Research
  4. 5.1.3 Other
  5. 5.2 Global Peptide CDMO Sales Value by Application
  6. 5.2.1 Global Peptide CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide CDMO Sales Value by Application (2021-2032)
  8. 5.2.3 Global Peptide CDMO Sales Value Share by Application (2021-2032)
6 Peptide CDMO Regional Value Analysis
  1. 6.1 Global Peptide CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peptide CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peptide CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Peptide CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peptide CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Peptide CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peptide CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peptide CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peptide CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Peptide CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peptide CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peptide CDMO Sales Value Share by Country, 2025 VS 2032
7 Peptide CDMO Country-level Value Analysis
  1. 7.1 Global Peptide CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peptide CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peptide CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peptide CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peptide CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peptide CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peptide CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peptide CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peptide CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peptide CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peptide CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peptide CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peptide CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peptide CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peptide CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peptide CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peptide CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peptide CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peptide CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peptide CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peptide CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peptide CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peptide CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peptide CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peptide CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peptide CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peptide CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peptide CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peptide CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peptide CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peptide CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peptide CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peptide CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peptide CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Xinbang Pharma
  2. 8.1.1 Xinbang Pharma Company Information
  3. 8.1.2 Xinbang Pharma Business Overview
  4. 8.1.3 Xinbang Pharma Peptide CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
  6. 8.1.5 Xinbang Pharma Recent Developments
  7. 8.2 ScinoPharm
  8. 8.2.1 ScinoPharm Company Information
  9. 8.2.2 ScinoPharm Business Overview
  10. 8.2.3 ScinoPharm Peptide CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ScinoPharm Peptide CDMO Product Portfolio
  12. 8.2.5 ScinoPharm Recent Developments
  13. 8.3 SN Biopharm
  14. 8.3.1 SN Biopharm Company Information
  15. 8.3.2 SN Biopharm Business Overview
  16. 8.3.3 SN Biopharm Peptide CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SN Biopharm Peptide CDMO Product Portfolio
  18. 8.3.5 SN Biopharm Recent Developments
  19. 8.4 Genscript
  20. 8.4.1 Genscript Company Information
  21. 8.4.2 Genscript Business Overview
  22. 8.4.3 Genscript Peptide CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Genscript Peptide CDMO Product Portfolio
  24. 8.4.5 Genscript Recent Developments
  25. 8.5 AmbioPharm
  26. 8.5.1 AmbioPharm Company Information
  27. 8.5.2 AmbioPharm Business Overview
  28. 8.5.3 AmbioPharm Peptide CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AmbioPharm Peptide CDMO Product Portfolio
  30. 8.5.5 AmbioPharm Recent Developments
  31. 8.6 USV Peptides
  32. 8.6.1 USV Peptides Company Information
  33. 8.6.2 USV Peptides Business Overview
  34. 8.6.3 USV Peptides Peptide CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 USV Peptides Peptide CDMO Product Portfolio
  36. 8.6.5 USV Peptides Recent Developments
  37. 8.7 Thermofischer
  38. 8.7.1 Thermofischer Company Information
  39. 8.7.2 Thermofischer Business Overview
  40. 8.7.3 Thermofischer Peptide CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Thermofischer Peptide CDMO Product Portfolio
  42. 8.7.5 Thermofischer Recent Developments
  43. 8.8 PolyPeptide
  44. 8.8.1 PolyPeptide Company Information
  45. 8.8.2 PolyPeptide Business Overview
  46. 8.8.3 PolyPeptide Peptide CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 PolyPeptide Peptide CDMO Product Portfolio
  48. 8.8.5 PolyPeptide Recent Developments
  49. 8.9 Piramal Pharma
  50. 8.9.1 Piramal Pharma Company Information
  51. 8.9.2 Piramal Pharma Business Overview
  52. 8.9.3 Piramal Pharma Peptide CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Piramal Pharma Peptide CDMO Product Portfolio
  54. 8.9.5 Piramal Pharma Recent Developments
  55. 8.10 JPT
  56. 8.10.1 JPT Company Information
  57. 8.10.2 JPT Business Overview
  58. 8.10.3 JPT Peptide CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 JPT Peptide CDMO Product Portfolio
  60. 8.10.5 JPT Recent Developments
  61. 8.11 CPC Scientific
  62. 8.11.1 CPC Scientific Company Information
  63. 8.11.2 CPC Scientific Business Overview
  64. 8.11.3 CPC Scientific Peptide CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CPC Scientific Peptide CDMO Product Portfolio
  66. 8.11.5 CPC Scientific Recent Developments
  67. 8.12 CordenPharma
  68. 8.12.1 CordenPharma Company Information
  69. 8.12.2 CordenPharma Business Overview
  70. 8.12.3 CordenPharma Peptide CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CordenPharma Peptide CDMO Product Portfolio
  72. 8.12.5 CordenPharma Recent Developments
  73. 8.13 CBL
  74. 8.13.1 CBL Company Information
  75. 8.13.2 CBL Business Overview
  76. 8.13.3 CBL Peptide CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CBL Peptide CDMO Product Portfolio
  78. 8.13.5 CBL Recent Developments
  79. 8.14 Bio Basic
  80. 8.14.1 Bio Basic Company Information
  81. 8.14.2 Bio Basic Business Overview
  82. 8.14.3 Bio Basic Peptide CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bio Basic Peptide CDMO Product Portfolio
  84. 8.14.5 Bio Basic Recent Developments
  85. 8.15 Bachem
  86. 8.15.1 Bachem Company Information
  87. 8.15.2 Bachem Business Overview
  88. 8.15.3 Bachem Peptide CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bachem Peptide CDMO Product Portfolio
  90. 8.15.5 Bachem Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst